drugset
drugset / Trial / NCT02170792

Bioavailability of BIBR 953 ZW After Dose of BIBR 1048 MS

NCT02170792 ↗

Phase 1 Completed 30 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

To assess the extent of absorption of 12.5, 50 and 200 mg of BIBR 1048 MS with and without coadministration of 150 mg ranitidine.

Timeline

Start
2001-02
Primary completion
2001-03
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Dabigatran etexilate Unknown 12.5 mg Oral
Subject Dabigatran etexilate Unknown 50 mg Oral
Subject Dabigatran etexilate Unknown 200 mg Oral
Subject Ranitidine Unknown 150 mg —

Indications

No indication recorded.